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Previewswith a proteomics approach involving the
sequencing and characterization of
protein subunits of MYSM1 complexes
purified from B-lineage progenitors.
Nonetheless, the findings of Jiang et al.
highlight a major epigenetic switch that
needs to be activated by targeted H2A
deubiquitination of nucleosomes that
span the promoter and enhancer region
of theEbf1 gene to start off B cell develop-
ment. That is quite A-MYSM!
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In this issue of Immunity, Duprez et al. (2011) demonstrate that necroptosis, a form of regulated necrosis
that is mediated by the kinases RIPK1 and RIPK3, underlies the lethal effects of tumor necrosis factor
in vivo.The discovery that death receptors can—
at least in specific circumstances—initiate
either apoptotic or necrotic cell death
(Vercammen et al., 1998) has ignited an
intense wave of investigation. As a result,
nearly 15 years later, necrosis is no
longer considered as a merely accidental
cell death subroutine and the molecular
mechanisms that control regulated
necrosis have begun to emerge (Galluzzi
et al., 2012). One of the best-character-
ized signaling cascades that leads to
necrotic cell death is triggered by the liga-
tion of death receptors, mainly tumor
necrosis factor receptor 1 (TNFR1), in
conditions inwhich caspases, in particular
caspase-8, are inactivated (by pharmaco-
logical agents, the transfection of viral
proteins with caspase-inhibitory func-
tions, or genetic means) (Vandenabeeleet al., 2010). This peculiar form of regu-
lated necrosis, necroptosis, requires
the kinase activity of the TNFR1 interactor
receptor-interacting protein kinase 1
(RIPK1) as well as of its close homolog
RIPK3 and is executed by a bioenergetic
catastrophe featuring the overgeneration
of reactive oxygen species and increased
metabolic fluxes through glycolysis,
glycogenolysis, and glutaminolysis (Van-
denabeele et al., 2010). It has become
clear that necroptosis plays an important
role in multiple pathophysiological set-
tings, including ischemia-reperfusion
injury, cerulein-induced acute pancrea-
titis, viral infection, and retinal detach-
ment-induced photoreceptor cell death
(Vandenabeele et al., 2010). Moreover,
accumulating evidence indicates that pro-
apoptotic proteins including caspase-8and FADD are critical for embryonic and
postembryonic development as they toni-
cally inhibit regulated necrosis (Kaiser
et al., 2011; Zhang et al., 2011). In this
issue of Immunity, Duprez et al. (2011)
demonstrate that necroptosis constitutes
a prime etiological determinant for
both systemic inflammatory response
syndrome (SIRS) and hypoinflammatory
sepsis. In doing so, these authors not
only add two entries to the ever-growing
list of clinically relevant conditions that
may benefit from necroptosis-targeted
therapies, but also cast doubts on the
long-standing notion whereby the lethality
of SIRSwould directly result from a ‘‘cyto-
kine storm’’ associated with multiorgan
failure (Hotchkiss and Karl, 2003).
As a first step to elucidate the relative
contribution of apoptotic and necroticecember 23, 2011 ª2011 Elsevier Inc. 849
Figure 1. Apoptosis and Necroptosis Contribute to Hyperinflammatory Shock and
Hypoinflammatory Sepsis in a Tissue-Specific Manner
Tumor necrosis factor a (TNF) can be massively generated in the context of hyperinflammatory shock or
slowly accumulate upon infection (owing to the innate immune response against pathogen-associated
molecular patterns, PAMPs). In the intestine, TNF triggers the sequential activation of caspase-8 and cas-
pase-3, leading to extensive cell death via apoptosis. Conversely, in the liver, after an initial wave of secre-
tion of proinflammatory interleukin-1 (IL-1) and IL-6, TNF initiates receptor-interacting protein kinase 3
(RIPK3)-dependent necroptosis. This results in themassive release into the bloodstream of damage-asso-
ciated molecular patterns (DAMPs), in turn promoting a delayed but sustained production of IL-1 and IL-6
(and perhaps other proinflammatory modulators). As demonstrated by Duprez et al. (2011), neither
the apoptotic demise of intestinal epithelial cells nor the early wave of circulating cytokines are
responsible for shock-associated mortality. Rather, it appears that RIPK3-dependent necroptosis in
the liver (and possibly other organs)—leading to a massive and prolonged release of DAMPs into the
circulation —constitutes a prime etiological determinant for both hyperinflammatory shock and hypoin-
flammatory sepsis.
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Previewsregulators to TNF-induced SIRS, Duprez
et al. studied how TNF-induced necropto-
sis is affected in vitro by the broad-
spectrum caspase inhibitor Z-VAD-fmk
or by the absence of initiator (caspase-8)
or executioner (caspase-3 and -7) cas-
pases. In line with recent results, they
found that Z-VAD-fmk and the depletion
of caspase-8 exacerbate the necroptotic
response to TNF of murine fibrosarcoma
L929 cells to similar extents, and in a
noncumulative fashion, whereas the
knockdown of caspase-3 and caspase-7
(alone or in combination) had virtually no
effects. Prompted by these observations,
Duprez et al. moved to an in vivo setting
and compared TNF-induced SIRS in
wild-type (WT) mice versus mice that
lacked, because of homologous gene
recombination, either executioner cas-
pases (caspase-3 or -7), or inflammatory
caspase-1, which is essential for the
maturation and secretion of the cytokines
IL-1b and IL-18. In contrast to their
WT counterparts, Casp3/ mice failed850 Immunity 35, December 23, 2011 ª2011to manifest extensive intestinal damage,
featuring severe immune cell infiltration
and intestinal epithelial cell apoptosis, in
response to TNF. However, TNF-induced
hypothermia (the first symptom of SIRS),
the amounts of circulating damage-
associated molecular patterns (DAMPs)
and mortality were comparable in all
groups of mice, demonstrating that (1)
neither apoptotic executioner caspases
nor proinflammatory caspase-1 are re-
quired for the development of SIRS,
even though caspase-3 underlies its
intestinal (non causal) manifestations,
and (2) that none of these proteins consti-
tutes the molecular target of Z-VAD-fmk,
which does exacerbate TNF-induced
shock in vivo (Cauwels et al., 2003). Of
note, the Casp8/ genotype could not
be tested because it is associated with
early embryonic lethality (Varfolomeev
et al., 1998).
Duprez et al. then checked whether the
essential necroptotic regulator RIPK3
affects SIRS in vivo. TNF-treatedRipk3/Elsevier Inc.mice maintained thermal homeostasis
better than their WT counterparts, corre-
lating with markedly improved survival.
Moreover, whereas WT mice responded
to the systemic administration of TNF
with a time-dependent increase in the
plasma amount of DAMPs (including
distinct intracellular proteins as well as
mitochondrial DNA) from several tissues,
their Ripk3/ littermates exhibited an
initial (modest) augmentation of circu-
lating DAMPs that was often followed
by a decrease. Of note, the absence
of Ripk3 protected the liver from TNF-
induced focal necrosis, but failed to
ameliorate the intestinal damage pro-
voked by TNF (Duprez et al., 2011). To
test their hypothesis in another model
of deficient necroptosis while circum-
venting the fact that Ripk1/ mice die
soon after birth (Kelliher et al., 1998),
Duprez et al. employed necrostatin-1
(Nec-1, a pharmacological inhibitor of
the enzymatic activity of RIPK1), fully
recapitulating the results obtained in
Ripk3/ mice. These observations sug-
gest that both apoptosis and necrop-
tosis are activated— though in distinct
tissues—during SIRS, yet only the latter
constitutes one of its etiological determi-
nants (Figure 1). To confirm their findings
in a more clinically relevant setting,
Duprez et al. took advantage of the cecal
ligation and puncture (CLP) model, better
reflecting the microbial-induced hypoin-
flammatory condition that often deter-
mines the death of septic patients (Hotch-
kiss and Karl, 2003). In two distinct
experimental settings (mild and severe
CLP), Ripk3/ mice were capable of
recovering body temperature better, ex-
hibited lower DAMP release into the
bloodstream, and survived at higher
rates than their WT littermates, even
though mice from both genotypes were
shown to bear comparable post-CLP
bacteremia (Duprez et al., 2011). Alto-
gether, these results underscore an
important role for RIPK3-dependent nec-
roptosis in both hyper- and hypoinflam-
matory shock conditions.
For a long time, shock-related mortality
has been ascribed to the harmful effects
of the so-called ‘‘cytokine storm,’’ i.e.,
the near-to-simultaneous systemic re-
lease of dozens of different pro- and
anti-inflammatory cytokines driven by
TNF, IL-1, and IL-6 (Hotchkiss and Karl,
2003). To monitor whether and how
Immunity
Previewsnecroptosis might influence this aspect of
the hyperinflammatory shock, Duprez
et al. monitored the plasma concentra-
tions of IL-1 and IL-6 upon systemic TNF
administration. Unexpectedly, both WT
and Ripk3/ mice (as well as mice that
had been pretreated with Nec-1) ex-
hibited an early (2 hr after TNF injection)
increase in circulating IL-1 and IL-6.
However, whereas inWTmice the plasma
concentrations of IL-1 and IL-6 nearly
doubled 4 hr later (that is 6 hr after the
administration of TNF), in Ripk3/ (as
well as in Nec-1-pretreated) animals they
regressed to near-to-baseline amounts
(Duprez et al., 2011). Thus, necroptosis-
proficient and -deficient mice did not
differ from each other relative to the early
wave of cytokine secretion that is
believed to be a direct consequence of
the administration of TNF. Still, they
behaved in a markedly distinct fashion
with respect to the delayed production
of proinflammatory modulators, which
the authors hypothesize to be stimulated
by circulating DAMPs. Although this latter
point remains to be formally demon-
strated, the results by Duprez et al. argue
against a causal role for the early wave of
cytokine release in the development of
SIRS, in turn casting some doubts on
the actual contribution of the cytokinestorm to shock-associated mortality in
clinical settings.
The discovery that necrosis does not
constitute a merely accidental cell death
mode but also can occur in a finely regu-
lated fashion has generated great clinical
and therapeutic expectations. On one
hand, anticancer therapies that trigger
the necrotic death of tumor cells may be
particularly suitable for the eradication of
apoptosis-resistant malignancies. On the
other hand, avoiding the unwarranted
necrotic demise of postmitotic cells may
turn out to be beneficial in an ever-
growing list of clinically relevant condi-
tions in which regulated necrosis is in-
volved as a causal determinant. This list
now includes hyperinflammatory shock
and hypoinflammatory sepsis. Although
the underlying molecular and cellular
mechanisms, in particular the link(s)
between circulating DAMPs and the
delayed wave of cytokine release, have
not been precisely elucidated, the
work by Duprez et al. suggests that
necroptosis-targeting agents may consti-
tute a valuable alternative to anti-inflam-
matory therapies and cytokine blockers
for the treatment of shock. Future will
tell whether these compounds will make
all their way from the bench to the
bedside.Immunity 35, DREFERENCES
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Plasmacytoid dendritic cells (pDCs) have potential influence on innate and adaptive immune responses. In
this issue of Immunity, Takagi et al. (2011) established mice lacking pDCs and explored the impact of pDC
ablation in vivo.Plasmacytoid dendritic cells (pDCs), also
known as type I interferon-producing cells
(IPCs), are specialized cells of the immune
system that rapidly secrete massive
amounts of type I interferon after activa-tion via Toll-like receptor 7 (TLR7) and/or
TLR9 by sensing pathogenic nucleic
acids. Subsequent to type I IFN produc-
tion, activated pDCs differentiate into
a unique type of mature DC and acquirethe ability to activate T cells (Liu, 2005).
Previous studies show that regardless of
their maturation stage and activation
signals, pDCs have an intrinsic ability to
prime naive T cells to differentiate intoecember 23, 2011 ª2011 Elsevier Inc. 851
